High-Value Federal Grants ($5M+) — April 01, 2026

Four contracts totaling $2.06B awarded to RTX/Raytheon ($1.22B), Lockheed ($301M), TRAX ($406M), and Caltech ($134M) for instruments, vehicles, and support through 2029.

Contracts average 10+ year spans (e.g., Raytheon to 2029, Sevenson to 2032) with $1.1B+ already outlayed across portfolio, locking in low-competition streams.

Unobligated options exceed $630M across deals (e.g., HII $509M, Raytheon $32M), exercisable via performance milestones.

Extended timelines (18+ years for Raytheon, 8 years for Sevenson) with low outlays on key deals (e.g., Lockheed $44M/301M, Sevenson $0/180M) heighten funding and delivery risks.

Cost-plus-award-fee (7/8 contracts) links ~70% of value to govt evaluations; foreign ownership in Emergent Canada invites sourcing scrutiny.

Near-term expirations (TRAX 2024, HII 2025) risk $852M revenue cliff without renewals.

$630M+ in exercisable options and follow-ons from NASA/DoD repeats (e.g., TRAX reissue, Raytheon VIRS support).

Environmental remediation ($180M Sevenson) and biotech stockpiles ($256M Emergent) signal rising DoD/HHS priorities.

Undrawn obligations total ~$1.5B (e.g., Raytheon $908M remaining), offering backlog visibility at low competition.

67% of value ($2.06B) in space vehicles/instruments/logistics to primes and FFRDCs, with 3/4 cost-plus through 2029.

87% of contracts use cost-plus structures, minimizing primes' margin risk but tying to performance.

{"entity"=>"RTX/Raytheon NASA VIRS", "reason"=>"$1.22B (40% of total) with $908M undrawn through 2029.", "trigger"=>"option exercise >$32M or outlay >20% YoY"}

{"entity"=>"TRAX International", "reason"=>"$406M NASA logistics nearing 2024 end with $118M remaining.", "trigger"=>"extension to Oct 2024 or follow-on award"}

{"entity"=>"Sevenson Environmental", "reason"=>"Fresh $180M DoD remediation win, $0 outlay, 8-year term.", "trigger"=>"initial outlays or subawards >$10M"}